11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA
Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Reports Second Quarter 2025 Financial Results and Business Update
News, Letter Re Change in Certifying Accountant
Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News, Material Contracts
Reports Third Quarter 2024 Financial Results and Recent Highlights
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Definitive Information Statement
Preliminary Information Statement
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence